Clinical Features and Insulin Resistance in Men with a Metabolically Unhealthy Obesity Phenotype

Purpose of the study: The aim of study was to analyze the characteristics of hormonal-metabolic parameters in men with a metabolically unhealthy obesity phenotype; identify the value of special indicators for diagnosis of insulin resistance.

Materials and methods: The examination included 108 patients with body mass index ≥25 kg/m2, which were hospitalized. According to the current national guidelines for the diagnosis and treatment of obesity, all examined patients were divided into 2 groups: 1 — with metabolically healthy obesity phenotype, 2 — with metabolically unhealthy obesity phenotype. The study presents the results of comparative simultaneous nonrandomized study of two groups with using of different methods of examination (anthropometric indicators, laboratory tests for inspection of the hormonal profile, biochemistry parameters, and calculation of TyG index for diagnosis of insulin resistance).

Results and discussion: The study found that patients of working age with metabolically unhealthy obesity phenotype are characterized by unfavorable anthropometric and hormonal-metabolic parameters and more severe polymorbid pathology (first of all cardiovascular diseases). The results of study revealed the value of special indicators for the diagnosis of insulin resistance (visceral obesity index >1,85; TyG >3,98; fat mass >30,1).

Conclusion: timely detection of insulin resistance indicators has great importance and practical application due to simplicity and accessibility. 

1. Romancova T.I. The obesity epidemic: obvious and probable causes. Obesity and metabolism. 2011; 1: 5-17. [In Russian].

2. Lins L., Carvalho F.M. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med. 2016; 4: 2050312116671725. doi:10.1177/2050312116671725.

3. Krasil’nikova E.I., Blagosklonnaya YA.V., Bystrova A.A et al. Adiposopathy is a key element in the development of insulin resistance. Arterial Hypertension. 2012; 18(2): 165-76. doi. org/10.18705/1607-419X-2012-18-2-164-176 [in Russian].

4. Kurshakova L.N., SHabanova G.F., SHarifullina E.R. et al. Insulin resistance and carbohydrate metabolism disorders in metabolic syndrome in males. Kazan medical journal. 2009; 90 (2): 239-43 [in Russian].

5. Beltrán-Sánchez H., Harhay M.O., Harhay M.M. et al. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010. J Am Coll Cardiol. 2013; 62(8): 697-703. doi: 10.1016/j. jacc.2013.05.064.

6. Kushner R.F., Kahan S. Introduction: The State of Obesity in 2017. Med Clin North Am. 2018; 102(1): 1-11. doi: 10.1016/j.mcna.2017.08.003.

7. Du T., Sun X., Yin P. et al. Secular trends in the prevalence of low risk factor burden for cardiovascular disease according to obesity status among Chinese adults, 1993–2009. BMC Public Health. 2014; 14: 961. doi: 10.1186/1471-2458-14-961.

8. Diagnosis, treatment, prevention of obesity and associated diseases. National clinical guidelines. Russian Cardiology Society. Russian Scientific Medical Society of Therapists. Antihypertensive League. Association of Clinical Pharmacologists. 2017: 3-164. [in Russian].

9. Nedogoda S.V., Barykina I.N., Salasyuk A.S. National clinical recommendations for obesity: concept and prospects. Vestnik of Volgograd Medical University. 2017; 1(61): 134-9. [in Russian].

10. Gallagher D., Heymsfield S.B., Heo M. et al. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. The American journal of clinical nutrition. 2000; 72(3): 694-701. doi: 10.1093/ajcn/72.3.694.

11. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27(6): 1487-95. doi: 10.2337/ diacare.27.6.1487.

12. Lee J.W., Lim N.K., Park H.Y. The product of fasting plasma glucose and triglycerides improves risk prediction of type 2 diabetes in middle-aged Koreans. BMC Endocr Disord. 2018;18(1):33. doi: 10.1186/ s12902-018-0259-x.

13. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Letters. 2006; 580(12): 2917-21. doi: 10.1016/j.febslet.2006.04.028.

14. Maeda N., Shimomura I., Kishida K. et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002; 8(7): 731-7. doi: 10.1038/nm724.

15. Anari R., Amani R., Latifi S.M. et al. Association of obesity with hypertension and dyslipidemia in type 2 diabetes mellitus subjects. Diabetes Metab Syndr Clin Res Rev. 2017; 11(1): 37-41. doi: 10.1016/j. dsx.2016.07.004.

16. Adamska A., Nikolajuk A., Karczewska-Kupczewska M. et al. Relationships between serum adiponectin and soluble TNF-a receptors and glucose and lipid oxidation in lean and obese subjects. Acta Diabetol. 2012; 49(1): 17-24. doi: 10.1007/s00592-010-0252-y

17. Amato M.C., Giordano C., Pitrone M. et al. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis. 2011; 10: 183. doi:10.1186/1476-511X-10-183.

18. Mohammadreza B., Farzad H., Davoud K. et al. Prognostic significance of the complex «Visceral Adiposity Index» vs. simple anthropometric measures: Tehran lipid and glucose study. Cardiovasc Diabetol. 2012; 11: 20. doi:10.1186/1475-2840-11-20.